(Q35194407)

7 August 2017

1 reference

title

Safety profile of the triptans (English)

1 reference

7 August 2017

1

Stewart J Tepper

1 reference

7 August 2017

David Millson

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

Expert Opinion on Drug Safety

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

123-132

1 reference

Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Safety and rational use of the triptans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Is chest pain after sumatriptan oesophageal in origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Serotonin syndrome complicating migraine pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Rizatriptan in the treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.2.123

21 January 2018

Identifiers

DOI

10.1517/14740338.2.2.123

1 reference

7 August 2017

1 reference